Comprehensive Analysis of Candidate Diagnostic and Prognostic Biomarkers Associated with Lung Adenocarcinoma

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2020 Jun 25

PMID 32578582

Citations 5

Authors

Jingyuan Li

Xingyuan Liu

Zan Cui

Guanying Han

Affiliations

Soon will be listed here.

Abstract

BACKGROUND We aimed to screen and identify central genetic and molecular targets involved in advancement of lung adenocarcinoma (LUAD) and to perform an integrated analysis and clinical validation. MATERIAL AND METHODS The GEO2R technique was utilized to assess differentially expressed genes (DEGs) among the gene sets GSE75037, GSE85716, and GSE118370. Subsequently, gene Ontology (GO) analyses and Kyoto Encyclopedia of Genes and Genomes (KEGG) analytical methods were executed to determine related biofunctions and signaling pathways, which were annotated with tools from the Database for Annotation, Visualization and Integrated Discovery (DAVID) resource. Then, a protein-protein interaction (PPI) network complex consisting of all detected DEGs was built with the STRING web interface. Cytohubba and MCODE plug-ins for Cytoscape software and Gene Expression Profiling Interactive Analysis (GEPIA) were employed to identify the hub genes. Finally, the mRNA expression of the identified hub genes was quantitatively validated by The Cancer Genome Atlas (TCGA) database analysis and real-time quantitative polymerase chain reaction (RT-qPCR). RESULTS We screened 146 upregulated DEGs and 431 downregulated DEGs with the criteria of |logFC| >1 and P<0.05, and the GO analysis indicated that DEGs were implicated in mitotic nuclear division (biological process, BP), the nucleus (cellular component, CC), and protein binding (molecular function, MF) and were associated with multiple KEGG pathways, such as the p53 signaling pathway in cancer. Then, the top 8 genes that predicted significantly different outcomes in LUAD patients were filtered from the DEGs and selected as hub genes. The TCGA database analysis and RT-qPCR results demonstrated that these genes were differentially expressed with the same trends in LUAD tissues compared with normal tissues. CONCLUSIONS Overall, we propose that 8 genes (PECAM1, CDK1, MKI67, SPP1, TOP2A, CHEK1, CCNB1, and RRM2) might be novel hub genes strongly associated with the progression and prognosis of LUAD.

Citing Articles

AURKA, TOP2A and MELK are the key genes identified by WGCNA for the pathogenesis of lung adenocarcinoma.

Xu Y, Wang S, Xu B, Lin H, Zhan N, Ren J Oncol Lett. 2023; 25(6):238.

PMID: 37153047 PMC: 10161350. DOI: 10.3892/ol.2023.13824.

Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer.

Sial N, Saeed S, Ahmad M, Hameed Y, Rehman A, Abbas M Int J Gen Med. 2021; 14:7025-7042.

PMID: 34707394 PMC: 8544130. DOI: 10.2147/IJGM.S327367.

A Systematic Analysis Identifies Key Regulators Involved in Cell Proliferation and Potential Drugs for the Treatment of Human Lung Adenocarcinoma.

Wang K, Zhang M, Wang J, Sun P, Luo J, Jin H Front Oncol. 2021; 11:737152.

PMID: 34650921 PMC: 8505978. DOI: 10.3389/fonc.2021.737152.

CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes.

Sial N, Ahmad M, Hussain M, Iqbal M, Hameed Y, Khan M Sci Rep. 2021; 11(1):19873.

PMID: 34615943 PMC: 8494806. DOI: 10.1038/s41598-021-99321-w.

Construction and Analysis of a circRNA-Mediated ceRNA Network in Lung Adenocarcinoma.

Wang Z, Pei H, Liang H, Zhang Q, Wei L, Shi D Onco Targets Ther. 2021; 14:3659-3669.

PMID: 34135596 PMC: 8197624. DOI: 10.2147/OTT.S305030.

References

Warfel N, Dolloff N, Dicker D, Malysz J, El-Deiry W . CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle. 2013; 12(23):3689-701. PMC: 3903720. DOI: 10.4161/cc.26930. View

Kadota K, Yeh Y, DAngelo S, Moreira A, Kuk D, Sima C . Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. Am J Surg Pathol. 2014; 38(8):1118-27. PMC: 4666292. DOI: 10.1097/PAS.0000000000000246. View

Piao J, Zhu L, Sun J, Li N, Dong B, Yang Y . High expression of CDK1 and BUB1 predicts poor prognosis of pancreatic ductal adenocarcinoma. Gene. 2019; 701:15-22. DOI: 10.1016/j.gene.2019.02.081. View

Zhao P, Zhang P, Hu W, Wang H, Yu G, Wang Z . Upregulation of cyclin B1 plays potential roles in the invasiveness of pituitary adenomas. J Clin Neurosci. 2017; 43:267-273. DOI: 10.1016/j.jocn.2017.05.005. View

Abraham V, Cao G, Parambath A, Lawal F, Handumrongkul C, Debs R . Involvement of TIMP-1 in PECAM-1-mediated tumor dissemination. Int J Oncol. 2018; 53(2):488-502. PMC: 6017270. DOI: 10.3892/ijo.2018.4422. View

Sung W, Lin Y, Wu P, Yen H, Lai H, Su T . High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients. BMC Cancer. 2014; 14:951. PMC: 4302138. DOI: 10.1186/1471-2407-14-951. View

Batra A, Winquist E . Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer. Expert Opin Emerg Drugs. 2018; 23(4):271-282. DOI: 10.1080/14728214.2018.1547707. View

Barrett T, Wilhite S, Ledoux P, Evangelista C, Kim I, Tomashevsky M . NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2012; 41(Database issue):D991-5. PMC: 3531084. DOI: 10.1093/nar/gks1193. View

Shannon P, Markiel A, Ozier O, Baliga N, Wang J, Ramage D . Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11):2498-504. PMC: 403769. DOI: 10.1101/gr.1239303. View

10.

Xie Y, Wei R, Huang G, Zhang M, Yuan Y, Wang H . Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma. Med Oncol. 2014; 31(3):844. DOI: 10.1007/s12032-014-0844-4. View

11.

Baiocchi G, Poliseli F, De Brot L, Mantoan H, Schiavon B, Faloppa C . TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma. J Clin Pathol. 2016; 69(10):884-9. DOI: 10.1136/jclinpath-2015-203561. View

12.

Borges U, Costa-Silva D, da Silva-Sampaio J, Escorcio-Dourado C, Conde Jr A, Campelo V . A comparative study of Ki-67 antigen expression between luminal A and triple-negative subtypes of breast cancer. Med Oncol. 2017; 34(9):156. DOI: 10.1007/s12032-017-1019-x. View

13.

Bell R, Barraclough R, Vasieva O . Gene Expression Meta-Analysis of Potential Metastatic Breast Cancer Markers. Curr Mol Med. 2017; 17(3):200-210. PMC: 5748874. DOI: 10.2174/1566524017666170807144946. View

14.

Travis W, Brambilla E, Nicholson A, Yatabe Y, Austin J, Beasley M . The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015; 10(9):1243-1260. DOI: 10.1097/JTO.0000000000000630. View

15.

Behera M, Owonikoko T, Gal A, Steuer C, Kim S, Pillai R . Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. Clin Lung Cancer. 2016; 17(5):e57-e64. DOI: 10.1016/j.cllc.2016.03.009. View

16.

Peng Z, Wang J, Shan B, Yuan F, Li B, Dong Y . Genome-wide analyses of long noncoding RNA expression profiles in lung adenocarcinoma. Sci Rep. 2017; 7(1):15331. PMC: 5681506. DOI: 10.1038/s41598-017-15712-y. View

17.

Liu X, Yang Y, Liu X, Zhang M, Li R, Yin Y . A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma. J Transl Med. 2019; 17(1):50. PMC: 6380039. DOI: 10.1186/s12967-019-1800-z. View

18.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

19.

Huang C, Yu G, Wang W, Liu B, Sun Z . Prognostic and predictive values of SPP1, PAI and caveolin-1 in patients with oral squamous cell carcinoma. Int J Clin Exp Pathol. 2014; 7(9):6032-9. PMC: 4203219. View

20.

Nikolenyi A, Uhercsak G, Csenki M, Hamar S, Csorgo E, Tanczos E . Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy. Pathol Oncol Res. 2011; 18(1):61-8. DOI: 10.1007/s12253-011-9417-4. View